BCMA/CD19 CAR-T cell therapy for high-risk multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a new treatment called RN1201, which uses a patient's own immune cells to fight multiple myeloma that has high-risk genetic features. The goal is to see if this therapy can help control the disease better after initial treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with active multiple myeloma that has high-risk genetic changes, such as del(17p), t(4;14), or other specific abnormalities.
- Your myeloma cells must test positive for two markers called BCMA and CD19.
- You must have received at least one round of initial treatment (induction therapy) but not more than 4 cycles, and your disease should not have gotten worse.
- You must be at least 18 years old and be in reasonably good general health (able to perform daily activities with some help).
- Your heart, lungs, liver, and kidneys must be working well enough, as shown by standard lab tests.
- You must not have certain infections like HIV, hepatitis B, or hepatitis C, or other conditions that could make the treatment unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called RN1201 as a first-line treatment for multiple myeloma, a blood cancer. The study aims to see if it is safe and effective for patients who have never been treated for this condition before.
This trial tests a new immunotherapy called BCMA CAR-T for people with multiple myeloma that is considered high-risk. It aims to see if this treatment can help patients who had a short response to initial therapy or have specific genetic changes in their cancer.
This trial is testing a new immunotherapy treatment using CAR-T cells for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. The treatment aims to target and destroy myeloma cells that have BCMA and GPRC5D proteins on their surface.
This trial tests a new CAR-T cell therapy that targets two proteins (BCMA and CD19) on myeloma cells. It may help patients whose myeloma has come back or stopped responding to previous treatments.
This trial tests whether a newer immune treatment (BCMA CAR-T) works better than a stem cell transplant for people with multiple myeloma who are able to have a transplant. Both treatments aim to kill myeloma cells, but CAR-T uses your own engineered immune cells.
This trial tests a new type of immune cell therapy using donated umbilical cord blood cells that are modified to target two proteins (BCMA and CD19) on myeloma cells. It is for people whose multiple myeloma has come back or is not responding to at least three prior treatments, including a proteasome inhibitor, an immunomodulatory drug, or an anti-CD38 antibody.
Hear when a new Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma Patients Ineligible or Unwilling to Undergo ASCT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.